A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease

Clinical trial NCT07568535 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07568535
Sponsor: Mesoblast, Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

GVHD - Graft-Versus-Host Disease

Start date: 2026-08-31
Primary completion: 2028-02-28
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.